Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Sometimes – for no obvious reason – there is a flurry of publications from a particular area which has been quiet for a long time. RSV is such an area where new drug development had a hard time getting started. There was always the lure of big money: an infection Continue reading There is Momentum Building for RSV Therapeutics
In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2. Since then, it has been very quiet about this compound. Some have suggested that Novartis has stopped development [1], an impression supported by the fact that the drug is Continue reading Following The Publication Trail of Two RSV Drugs